About the Event
Our health depends on a variety of factors. Personalized medicine has benefited from the combination of a person’s DNA sequence with global and detailed molecular monitoring to assess a person’s physiological states and reduce our chances of developing certain diseases. But to maintain wellness and vitality, we need to have an active lifestyle integrated with an appropriate diet. Are our vital signs frequently monitored to prevent deterioration to our health? Do we have access to up-to-date expert medical advice, and are we alerted to follow it?
Our genetics, nutrition, sleep cycles, exercise routines, medical consultations, and many other health factors intermingle, each contributing tons of data to the assessment and enhancement of our overall health. How do we manage such a deluge of data effectively?
In this talk, Mike Snyder will discuss how wearables can be used for tracking and monitoring health in unexpected ways. He will also discuss the future of big data on managing our health.
- Please RSVP by 5 pm on April 18th
- Those who have not registered will have to wait at the door as registered alumni are seated first
- Pay at the door
- Registrants must pay whether they show up or not as we are charged based on the number of RSVPs we receive.
About the Speaker
Mike Snyder (PhD '81) is the Stanford Ascherman Professor and Chair of Department of Genetics. He is also the Director of the Center for Genomics and Personalized Medicine.
He received his Ph.D. at Caltech and his postdoctoral at Stanford. A leader in the field of functional genomics and proteomics, Mike is one of the major participants of the ENCODE project.
His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These techniques include the development of proteome chips; high resolution tiling arrays for the entire human genome; methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq); paired end sequencing for mapping of structural variation in eukaryotes; and de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes, and regulatory networks.
Seminal findings from the Snyder laboratory include the discovery that more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs between and within species.
Mike has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Tehcnologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.
Further, Mike is the author of the book, “Genomics and Personalized Medicine: What Everyone Needs to Know.”
Questions? Contact: Peter Tong: firstname.lastname@example.org